| 2025/09 - 九個月 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | 盈利能力分析 |
| 淨資產收益率 ROE (%) | -3.628 | -6.879 | -14.929 | -0.614 | 11.966 |
| 總資產報酬率 ROA (%) | -3.120 | -6.058 | -12.770 | -0.521 | 10.373 |
| 投入資產回報率 ROIC (%) | -3.451 | -6.645 | -14.132 | -0.566 | 11.071 | 邊際利潤分析 |
| 銷售毛利率 (%) | 37.294 | 79.785 | 80.596 | 78.657 | 78.686 |
| 營業利潤率 (%) | -51.076 | -30.930 | -68.255 | 9.430 | 67.811 |
| 息稅前利潤/營業總收入 (%) | -49.846 | -41.749 | -71.178 | 5.609 | 70.558 |
| 淨利潤/營業總收入 (%) | -44.328 | -39.632 | -74.952 | -0.240 | 69.203 | 收益指標分析 |
| 經營活動淨收益/利潤總額(%) | 123.624 | 52.375 | 57.758 | -1,464.805 | -75.986 |
| 價值變動淨收益/利潤總額(%) | -14.432 | -42.915 | -55.126 | 1,708.919 | 169.396 |
| 營業外收支淨額/利潤總額(%) | -5.568 | 23.741 | 6.352 | -164.616 | 1.980 | 償債能力分析 |
| 流動比率 (X) | 4.198 | 9.043 | 3.718 | 1.423 | 2.199 |
| 速動比率 (X) | 3.517 | 8.079 | 3.079 | 1.203 | 1.950 |
| 資產負債率 (%) | 10.002 | 7.906 | 6.992 | 13.571 | 10.359 |
| 帶息債務/全部投入資本 (%) | 3.557 | 0.391 | 0.566 | 7.092 | 6.220 |
| 股東權益/帶息債務 (%) | 2,674.196 | 24,345.700 | 17,332.748 | 1,296.269 | 1,490.292 |
| 股東權益/負債合計 (%) | 843.912 | 1,108.008 | 1,265.802 | 612.512 | 837.013 |
| 利息保障倍數 (X) | 34.043 | 35.077 | -41.719 | 2.742 | 51.213 | 營運能力分析 |
| 應收賬款周轉天數 (天) | 164.921 | 103.234 | 125.947 | 211.052 | 255.369 |
| 存貨周轉天數 (天) | 210.117 | 407.533 | 356.911 | 340.998 | 283.525 |
002581 ST未名醫藥
按盤價 
7.240 -0.050 (-0.69%)
7.240 -0.050 (-0.69%)| 備註： | 報價延遲最少15分鐘，資料更新時間為 03/04/2026 16:30 |
